Biointron Weekly Reports
News
Biointron’s Q3 2024 Antibody Industry Report is out now! Dive into the latest trends, breakthroughs, and insights shaping the antibody industry. Gain exclusive insights into:
Thank you to everyone who came to visit us at the 22nd Annual Discovery on Target in Boston, and Biologics 2024 in San Diego last week! 🎊 If you missed out, don’t worry – you can reach our expert team at info@biointron.com or (732) 790-8340.
In our latest episode of the new Antibody ABCs video series, we define bispecific antibodies. Watch the playlist here.
This Week’s News
Trends – ADCs in Regulatory Review
Antibody-drug conjugates (ADCs) have seen significant developments in regulatory review, with several notable announcements in the past few weeks. Innate Pharma received FDA clearance for its investigational new drug (IND) application for IPH4502, a novel topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4. Nectin-4 is a cell membrane adhesion protein overexpressed in several solid tumors, including urothelial, breast, esophageal, lung, ovarian, and pancreatic cancers, with limited expression in normal tissues. This clearance is exciting as Nectin-4 is an emerging target in cancer therapy, with other successful ADCs like Padcev (enfortumab vedotin) already targeting this protein.
Similarly, Alentis Therapeutics also received FDA IND clearance for ALE.P02, a CLDN1-targeting ADC intended for squamous cancers. ALE.P02 is a first-in-class ADC designed by linking a tubulin inhibitor, a potent cancer drug, to an antibody that specifically targets a unique CLDN1 epitope exposed on cancer cells. This combination could be a powerful new tool to fight the many squamous cancers that overexpress CLDN1 with less toxicity than traditional cancer drugs. Phase 1/2 clinical trial in patients expected to start Q1 2025.
While these two announcements highlight growing support for advancing ADC technology, AstraZeneca and Daiichi Sankyo US ’s recent trial setback underscores the challenges in this space. Their ADC datopotamab deruxtecan (Dato-DXd), a rival to Gilead Sciences ' Trodelvy (sacituzumab govitecan), failed to improve overall survival in a phase 3 breast cancer trial, a reminder that despite breakthroughs in targeting mechanisms, clinical outcomes can still pose significant hurdles.
As more ADCs enter regulatory review, their approval and success depend on both innovative targeting approaches and clear clinical benefit, making these recent developments pivotal for the future of ADC therapies.
Upcoming Events
This week, we will be exhibiting at BIO Japan 2024 in Yokohama, Japan! The event will be held on October 9-11, 2024, in Pacifico Yokohama. Meet us at Booth #D-28!
Next week, Biointron will be participating in the Festival of Biologics 2024 - Europe, scheduled for October 15-17, 2024, at the Congress Center Basel in Switzerland. Schedule a meeting with us at Booth #922!
Recommended by LinkedIn
We are officially 2 weeks away from the Antibody Engineering & Therapeutics Asia 2024! Join Biointron at this premiere event in Kyoto, Japan on October 21-23, 2024. Meet us at Booth #15!
Promotions – 40% OFF Abinvivo Products! 📣
Explore Abinvivo, our brand for 𝐚𝐧𝐭𝐢𝐛𝐨𝐝𝐢𝐞𝐬 𝐟𝐨𝐫 𝑖𝑛 𝑣𝑖𝑣𝑜 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡! 🎁 Save on your project with our 𝐭𝐢𝐦𝐞-𝐥𝐢𝐦𝐢𝐭𝐞𝐝 𝐨𝐟𝐟𝐞𝐫𝐢𝐧𝐠 - 40% off sitewide!
Now with online checkout and 1 week delivery:
RushMab - Gene™ is your go-to solution for quick plasmid production, designed specifically for antibody-related research. We offer a 4-day turnaround, delivering high-quality, transfection-grade expression plasmids for IgG, Fab, VHH, and ScFv sequences. We provide quantities of 100 µg (sufficient for 100 ml culture) with scalability up to grams. Using the reliable pcDNA3.4 backbone, we also accommodate custom vectors. Each plasmid undergoes Sanger sequencing verification and endotoxin control, ensuring precision and safety.
New Products & Reports
Learn more about Biointron at www.biointron.com, or contact us at info@biointron.com and +1 (732) 790-8340.